Key facts
- Elysium Health’s last known valuation is $240.0M.
- It has raised $391.6M across 1 recorded rounds; the latest was Early Stage VC ($20.0M) in Oct 2016.
- Notable investors include General Catalyst, Gaingels, Calm Ventures, Western Technology Investment, Sprint VC — 28 tracked in total.
- Elysium Health has filed 1 Form D with the SEC, most recently Dec 2016 ($20.0M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Elysium Health
Funding rounds
1 roundsAbout Elysium Health
Producer of health supplements intended to turn critical scientific advancements into accessible consumer products. The company's supplements include a health product that is clinically validated to enhance and sustain NAD+ levels in humans, which decline with age, as well as provides an at-home test that helps people discover their biological age, enabling consumers to enhance their bodily cellular metabolism and maintain an enhanced immune system.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2014
- Employees
- 59
- Website
- elysiumhealth.com/
- Ownership
- Privately Held (backing)
Elysium Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elysium Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elysium Health in its N-PORT filings yet. We sweep new filings monthly.